Grifols SA (GRFS) saw its stock soar 5.04% in the intraday trading session on Thursday, following the company's release of its Q4 2024 earnings report. The Spanish healthcare giant, specializing in plasma-derived therapies and diagnostics, reported record revenues and adjusted EBITDA for the year, driven by robust growth in its core Biopharma division.
The company's Biopharma segment, which includes its immunoglobulin (IG) franchise, emerged as a standout performer. In Q4, IVIG sales witnessed a remarkable 15.6% increase, while the subcutaneous IG market experienced an impressive 52% growth year-to-date. This strong momentum in plasma-derived therapies, coupled with a solid performance in albumin sales, solidified Grifols' position as a market leader in this domain.
Furthermore, Grifols made significant strides in strengthening its financial health. The company successfully reduced its leverage ratio from 6.8x in Q1 2024 to 4.6x by the end of the year, demonstrating improved debt management. Moreover, the company generated robust free cash flow, exceeding its initial guidance with a year-end result of €267 million.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.